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Abstract
Background: Accurate staging of colorectal cancer (CRC) with clinicopathological parameters is important for
predicting prognosis and guiding treatment but provides no information about organ site of metastases. Patterns
of genomic aberrations in primary colorectal tumors may reveal a chromosomal signature for organ specific
metastases.
Methods: Array Comparative Genomic Hybridization (aCGH) was employed to asses DNA copy number changes in
primary colorectal tumors of three distinctive patient groups. This included formalin-fixed, paraffin-embedded tissue
of patients who developed liver metastases (LM; n = 36), metastases (PM; n = 37) and a group that remained
metastases-free (M0; n = 25).
A novel statistical method for identifying recurrent copy number changes, KC-SMART, was used to find specific
locations of genomic aberrations specific for various groups. We created a classifier for organ specific metastases
based on the aCGH data using Prediction Analysis for Microarrays (PAM).
Results: Specifically in the tumors of primary CRC patients who subsequently developed liver metastasis, KC-SMART
analysis identified genomic aberrations on chromosome 20q. LM-PAM, a shrunken centroids classifier for liver
metastases occurrence, was able to distinguish the LM group from the other groups (M0&PM) with 80% accuracy
(78% sensitivity and 86% specificity). The classification is predominantly based on chromosome 20q aberrations.
Conclusion: Liver specific CRC metastases may be predicted with a high accuracy based on specific genomic
aberrations in the primary CRC tumor. The ability to predict the site of metastases is important for improvement of
personalized patient management.
Background
Colorectal cancer (CRC) is the second leading cause of
cancer death in the Western world. Every year one mil-
lion people worldwide will develop CRC [1]. The overall
five-year survival is 57% and up to 50% of all patients
will eventually develop metastases. Metastases are
responsible for the great majority of cancer deaths,
mainly metastatic liver disease. Even with surgery and
modern chemotherapy most metastases are eventually
fatal.
Besides lymphatic and haematogenous dissemination,
CRC can spread into the intra-abdominal cavity and
cause peritoneal metastases (PM).
Of all patients who die of advanced colorectal cancer,
60-70% show evidence of liver metastasis. Even with the
use of targeted drugs, the overall survival in patients
with non-resectable CRC liver metastases is only
2-years. In patients with resectable liver metastasis a
5-year survival of 30% can be achieved and up to 20% of
the population will still be alive after 10 years. Eligibility
for hepatic surgery depends on the possibility that all
metastases are resectable and adequate liver preservation
can be maintained. Therefore early detection of liver
metastases is of utmost priority and will result in more
radical surgery and thus long term survival [2].
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any medium, provided the original work is properly cited.Similar to liver metastasis, peritoneal metastasis is uni-
formly seen as a fatal condition. However, in the last
decade survival has improved due to aggressive cytore-
ductive surgery in combination with hyperthermic intra-
peritoneal chemotherapy (HIPEC). Several predictors
of outcome after HIPEC treatment, such as complete-
ness of cytoreduction and number of affected intra-
abdominal tumor regions, have been described. Patients
who underwent complete cytoreduction in combination
with HIPEC showed a 5-year survival of 22-49%. Early
detection of peritoneal metastases will result in a better
cytoreduction and less affected intra-abdominal regions
[3]. In conclusion, early detection of liver and peritoneal
metastasis will result in a tailored follow-up program
and through this better patient outcome.
Accurate staging of CRC with clinicopathological
parameters is important in predicting prognosis and
guiding treatment but can currently not predict the site
of metastases. Therefore, understanding of the molecu-
lar and cellular mechanisms underlying colorectal cancer
formation, in particular progression to site of metastases
is of utmost importance.
The development of CRC arises and develops through
the adenoma-carcinoma sequence. This adenoma-
carcinoma sequence is a well defined pathway of
histopathological stages, each characterized by distinct
mutations in oncogenes and tumor suppressor genes [4,5].
Two molecular pathways have been well described; the
microsatellite instability and the chromosomal instability
pathway (reviewed by Jass et al) [4,6,7]. The majority of
CRC (85%) are chromosomally unstable [5], characterized
by allelic losses, chromosomal amplifications and translo-
cations [8], whereas mismatch repair deficiency is the
underlying cause of the remainder of CRCs.
Cardoso et al. reviewed multiple studies that have
reported on the existence of chromosomal abnormalities
and gene expression profiles in CRC [8]. With this
approach they described several specific chromosomal loci
and corresponding genes which play an important role in
colorectal cancer progression. A meta-analysis by Diep
et al. on 31 comparative genomic hybridization (CGH)
studies, comprising a total 859 CRCs, described chromo-
somal alterations that occurred early in the establishment
of primary CRC, as well as those that are present in the
different Dukes’ stages and in liver metastases [9].
So far, a number of chromosomal aberrations have
been related to liver metastases in CRC [9-13]. Metha et
al. studied the relation between the extent of chromoso-
mal instability and the survival of patients with liver
metastases. They showed that with a larger chromoso-
mally unstable fraction in the liver metastases, survival
for patients was better [14].
Various studies have described prognostic gene
expression profiles for CRC patients although these
profiles have very few genes in common [15-20]. Gene
expression profiles have been described for breast cancer
that predict site specific recurrence e.g., bone and lung
metastases [21-23]. However, gene expression or geno-
mic profiles in CRC that predict site specific recurrence
have not been well studied.
Here, we investigated genome-wide chromosomal
aberrations in defined groups of primary colorectal
tumors to determine copy number signatures for site
specific metastases. The understanding of the molecular
and cellular mechanisms underlying colorectal cancer
formation, progression to malignancy and site specific
metastases are important to perform targeted follow-up
a n de v e n t u a l l yd e v e l o pt a r g e t e dt h e r a p yi np a t i e n t s
with CRC.
Methods
Patients and Tumor Specimens
We have used formalin-fixed, paraffin embedded (FFPE)
primary colorectal tumors of three different groups. 356
patients were selected on the basis of their disease out-
come in follow-up. Patients, who had developed metas-
tases were treated in two specialized centers: liver
metastasis (LUMC), peritoneal metastasis (NKI-AVL),
whereas all of the non-metastasis group were treated for
their primary tumor at the NKI-AVL. For the metastatic
groups primary tumor material was obtained from sev-
eral different pathology laboratories in the Netherlands.
In total, 119 samples were retrieved, of which 98 sam-
ples remained after quality control. One group (n = 36)
were patients who have been treated with Isolated
Hepatic Perfusion (IHP) for the treatment of CRC
metastases confined to the liver (LM) [24]. The second
group (n = 37) were patients who have been treated
with hyperthermal intraperitoneal chemotherapy
(HIPEC) for the treatment of CRC metastases confined
to the peritoneum (PM) [25]. The third group (n = 25)
consisted of patients with CRC who did not develop
metastases (M0). In this M0 group only two patients
had a minimal follow-up of 12 months. All the others
had a follow-up of at least 36 months. That implicates
that 92% had a follow-up of at least 3-years. The M0
group showed a median follow-up of 103 months. The
LM and PM groups were carefully screened to ensure
these were free of distant metastases at time of treat-
ment, other than the liver or the peritoneal surface,
respectively [25,26]. For that reason we characterized
these two groups as single organ specific CRC metas-
tases. In this study none of the primary tumors were
treated neo-adjuvant with chemotherapy. We have used
anonymized patient tissue material of patients who were
consented for a HIPEC procedure (PM) or Liver perfu-
sion (LM), or had not opted out for making left-over tis-
sue available for research (M0), which followed standard
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approved by the institutional IRB’s or Board, which ever
one was appropriate. Tissue handling and anonymiza-
tion followed the Helsinki declaration.
Comparative Genomic Hybridization
DNA copy number changes were investigated using the
3.5 k bacterial artificial chromosomes (BAC) array per-
forming array comparative genomic hybridization (aCGH)
[27]. The human 3600 BAC/PAC genomic clone set, cov-
ering the full genome at 1 Mb spacing used for the pro-
duction of our arrays, was obtained from the Welcome
Trust Sanger Institute http://www.sanger.ac.uk/. Informa-
tion on this clone set can be obtained at the BAC/PAC
Resources Center Web Site http://bacpac.chori.org. The
whole library was spotted in triplicate on every slide. To
prevent slide batch spotting bias, samples were hybridized
in random order http://microarrays.nki.nl/.
DNA isolation was performed as described earlier [28].
Briefly, genomic DNA was isolated by proteinase K
digestion after deparaffination from 10 × 10 μmF F P E
tissue sections containing at least 70% tumor cells from
both the M0 and PM group. For the LM group DNA
was isolated from FFPE tissue block punches. These
punches were taken out of the tissue blocks in the area
with at least 60% tumor cells. Reference DNA was iso-
lated from peripheral blood lymphocytes from six
healthy male individuals. It was pooled and sonicated
until its median fragment length was similar to that of
the test samples.
DNA quality was tested by measuring the maximum
possible length of DNA to be amplified by a multiplex
PCR as described elsewhere [29]. This mulitplex PCR
produces DNA fragments of 100, 200, 300, and 400 bp.
Samples of which at least 200 base pair fragments could
be produced were of sufficient quality to be analyzed
with aCGH [29] We initially selected 119 cases of which
98 passed the quality control. There were no significant
differences in tumor/patient characteristics in the
selected versus initial group.
Tumor DNA labelling was performed with ULS-Cy3
and ULS-Cy5 conjugates from the Universal Linkage
System (ULS Kreatech Biotechnology, Amsterdam the
Netherlands) [30]. Hybridisations on the arrays were
done at our Central Microarray Facility, as described
previously [27]. Data processing of the scanned microar-
ray slide included signal intensity measurement with the
ImaGene software program, followed by median pin-tip
(c.q. sub array) normalization. Intensity ratios (Cy5/Cy3)
were log2-transformed and triplicate spot measurements
were averaged [27]. Microarray data have been deposited
in NCBI’s Gene Expression Omnibus (Edgar et al
Nucleic Acids Res 2002) and are accessible through
GEO Series accession numbers GSE20496.
For MSI analyses, DNA from paired normal and
tumor samples was evaluated after PCR and fragments
were analyzed using 2 mononucleotide markers (BAT
25 and BAT 40), and 6 dinucleotide markers (D1S158,
D2S123, D5S346, D9S63, D17S250 and D18S58). A
tumor was considered to be MSI-high in case three or
more markers showed instability, MSI-low when only
one marker showed instability and MSI-stable when
none of the markers showed instability [16].
Data analysis
KC-SMART, a recently developed algorithm for identify-
ing recurrent copy number changes, was used to identify
specific locations of genomic gains and losses recurring
at significant levels within the various groups [31].
Briefly, an aggregate profile of the aberrations is created
by adding either the positive log2 values or the negative
log2 values across all tumors. These aggregate profiles
(one for gains and one for losses) are smoothed using
locally weighted Gaussian kernel convolution, resulting
in the Kernel Smoothed Estimate (KSE). KSEs computed
for many randomized instances of the dataset are
employed to generate a null distribution and establish a
(multiple testing corrected) significance threshold (p =
0.05, Figure 1). All aberrations in the smoothed profile
computed on the real data that exceed this threshold
are deemed to be significantly recurrent in the dataset.
In order to detect consistent differences in copy num-
ber changes between two groups, we employed compara-
tive KC-SMART. This approach employs the signal-to-
noise-ratio (SNR) to quantify the differences between the
profiles of two groups of tumors. The SNR is a ratio of
t h ea b s o l u t ed i f f e r e n c eo ft h em e a n so ft h ec l a s s e sa n d
the sum of the average within-class standard deviation,
analogous to the t-statistic. In order to calculate the SNR
we produce smoothed profiles as described above for sin-
gle tumors, instead of on an aggregate of the entire
group. This smoothed profile is constructed on a grid
with a grid spacing of 50,000 base pairs. For each grid
point we calculate the SNR between two groups. To
establish significance we permute the group labels 1000
times. Based on the results of this permutation, we are
able to calculate the false discovery rate (FDR), and define
a1 %F D Rt h r e s h o l d .A n yr e g i o nf o rw h i c ht h eS N R
exceeds this threshold, is significantly differentially aber-
rant between the two groups.
Logistic regression and its confidence intervals were
calculated using the glm and stats packages of the statis-
tical analysis software R http://www.r-project.org.
Approximate absolute copy numbers for a certain geno-
mic region were calculated from the averaged log2 mea-
surements over all BAC clones mapped to the region.
We created two classifiers for organ specific metas-
tases, using a shrunken centroids classifier (Prediction
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edu/~tibs/PAM) on the aCGH data. The first classifier
was trained to distinguish the LM group from a group
consisting of both the PM and M0 groups together. The
second classifier was trained to distinguish the PM
group from the M0 group (additional figures).
Results
Patient and tumor characteristics
Patient and tumor characteristics like gender, tumor dif-
ferentiation and MSI status, were not significantly differ-
ent between the three patient groups (M0, PM and LM
respectively) (Table 1). Groups differed for some charac-
teristics that could be partly accounted for by the differ-
ent selection criteria employed for each of the groups.
For instance, for the tumor location more right-sided
tumors were included in the M0 group, whereas the PM
and LM group consisted of more left-sided colon and
rectum tumors. There were relative more T4 tumors in
the PM group compared with the M0 and LM group.
Naturally, the M0 group showed no stage 4 patients and
was therefore significantly different from the LM and
PM group. The LM group had the highest percentage of
Stage 4 patients.
Almost all patients were MSI stable (including MSI
low) except for 1 patient in the PM group.
Comparative Genomic Hybridization and KC-SMART
analysis
Genomic DNA of 98 tumor samples was hybridized to
BAC-clone microarrays to obtain, for each BAC clone
o nt h ea r r a y ,al o g
2 ratio of the fluorescence intensity
ratio of the sample versus the reference for each of the
three groups. We first analyzed the three groups (LM,
PM, M0) separately with KC-SMART to detect regions
of common aberrations across the samples in a group.
See Figure 1.
The KC-SMART analysis showed that the three
groups had an overall similar pattern of chromosomal
aberrations, with the Pearson’s correlation coefficient
between the KSEs of the groups being 0.84 for the gains
and 0.90 for the losses (Figure 1). Although the genomic
instability in the three groups was similar overall, chro-
mosome 20 was an exception.
To better identify chromosomal aberrations specific for
the liver metastases group, we compared this group with
the other two groups (M0 and PM) combined (Figure 2
and 3). Chromosome 20q was significantly more gained
in the LM group compared with the other samples (Ker-
nel Smoothed Estimate (KSE); p < 0.05), Bonferroni mul-
tiple testing corrected, Figure 2 top panel, aberrations
exceeding the red lines). The comparative KC-SMART
analysis yielded chromosome 20q with a FDR < 0,01 and
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Figure 1 Visualisation of a three group KC-SMART analysis. This figure shows the Kernel Smoothed Estimated (KSEs) for the three groups
analyzed in this study (Liver Metastases (LM), Peritoneal Metastases (PM) and No metastases (M0)). All chromosomes are plotted head-to-tail,
Black dotted lines denote the end of chromosomes and magenta dotted line denote centromere locations.
Bruin et al. BMC Cancer 2010, 10:662
http://www.biomedcentral.com/1471-2407/10/662
Page 4 of 12Table 1 Patient and tumor characteristics No metastases (M0), Peritoneal Metastases (PM) and Liver Metastases (LM)
patients
M0 PM LM p-value**
25 Percentage 37 Percentage 36 Percentage
Gender Male 14 56% 21 57% 27 75%
Female 11 44% 16 43% 9 25% 0,185
Mean age at diagnosis 64,21 53,23 54,66
Location primary tumor Right colon 11 44% 11 30% 4 11%
Left colon 9 36% 22 59% 22 61%
Rectum 5 20% 4 11% 10 28% 0,027
T-status T1 0 0% 0 0% 0 0%
T2 0 0% 1 3% 4 11%
T3 21 84% 25 67% 30 84%
T4 4 16% 11 30% 1 3% 0,01
unknown 0 0% 0 0% 1 3%
N-status N0 19 76% 17 47% 13 36%
N+ 6 24% 19 53% 22 61% 0,01
unknown 0 0% 0 0% 1 3%
Stage 1 0 0% 1 3% 0 0%
2 16 64% 5 13% 3 8%
3 9 36% 13 35% 7 20%
4 0 0% 18 49% 26 72% 0
Presentation 0,009
Metachrone 25 100% 19 51% 8 22%
Synchrone 18 49% 26 72%
Unknown 0 0% 2 6% 1,00E-06
Differentiation Good 0 0% 3 8% 3 12%
Moderate 21 88% 27 73% 17 65%
Poor 3 13% 5 14% 6 23%
Other type 0 0% 2 5% 0 0% 0,3
Overall survival
Median in months (range) 103 (12-279) 22 (2-120) 26 (0-108)
MSI status Stable 21 91% 33 97% 30 100%
Low 2 9% 0 0% 0 0%
High 0 0% 1 3% 0 0% 0,124
Adjuvant treatment No 16 64% 25 68% 34 94%
Chemo 6 24% 12 32% 2 6%
Unknown 3 12% 0 0% 0 0% 0,014
** = Pearson Chi-Square Test
MSI status = Micro Satellite Instability status
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Page 5 of 12several other regions with a FDR of <0.05 (Figure 2; lower
panel). These other significant gains (FDR < 0.05) and
losses specific for the LM group were located on chromo-
somes 5q, 7q, 8p, 8q,13q, 14q, 15q, 18p, 18q (Figure 2;
lower panel and additional file 1 figure S1). Further inves-
tigation of the region gained on chromosome 20 showed
that BAC clones encompassing the whole q-arm are
gained in the LM group (Figure 3; KSE and SNR upper
and lower panel respectively).
Logistic regression analysis to predict liver metastases
recurrence based on the mean 20q profile of gains/losses
for each group separately, showed for every 0.1 log
2 20q
amplification an odds ratio of 16.2 (90% CI: 2.3-141.2)
for developing liver metastases. To test whether nodal
status and the 20q mean log
2 value are independent pre-
dictors of liver metastases, we added both terms to a
logistic regression and determined the significance of
the corresponding regression coefficients. Both coeffi-
cients were significant (20q: P < 0.00003, nodal status:
P < 0.024). This shows that our prediction of liver
metastases based on mean 20q log
2 value is independent
of nodal status.
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Figure 2 G a i n sa n dl o s s e so ft h eL i v e rM e t a s t a s e s( L M )s a m p l e sv e r s us the Peritoneal Metastases (PM) and No metastases (M0)
samples. Shown here is the KSE (Kernel Smoothed Estimated) of the LM and PM groups in the upper panel. The lower panel shows the signal-
to-noise (SNR) calculated between the two groups. The red dots represent the BAC clones used for the LM-PAM classifier. All chromosomes are
plotted head-to-tail, Black dotted lines denote the end of chromosomes and magenta dotted line denote centromere locations. FDR = False
Discovery Rate.
Bruin et al. BMC Cancer 2010, 10:662
http://www.biomedcentral.com/1471-2407/10/662
Page 6 of 12To investigate the predictive association of the
20q amplification we constructed a Receiver-Operator-
Characteristic curve (ROC-curve) for the average log
2
values of the chromosome 20q BAC clones. This simple
measure already results in an Area Under the Curve
(AUC) of 0.76 for predicting LM (Figure 4 red line).
A LM-PAM classifier was able to separate the LM
group from the other groups (M0 and PM) with 80%
accuracy ((Figure 5 misclassification error 20%) (78%
sensitivity and 86% specificity)). This LM-PAM classifier
included 84 BAC clones and was significantly enriched
for probes located on chromosome 20q (Additional file
2 table S1; marked green). Using the per-tumor class
probabilities derived from the PAM classifier we also
built a ROC-curve for this classifier which resulted in an
A U Co f0 . 8 6( F i g u r e4b l u el i n e ) .C h r o m o s o m e2 0i s
represented by 65 BAC clones on the BAC-array; 21 of
these clones represent the p-arm and 44 the q-arm.
From these 44 q-arm clones, 77% (34/44) were included
in the LM-PAM classifier (Table 2; marked bold-italic).
The rest of the BAC clones (50/84) in the LM-PAM
classifier were distributed over 20 different chromoso-
mal locations (Figure 2; lower panel and (Additional file
2 table S1).
The second classifier was trained to distinguish the PM
group from the M0 group. A PM-PAM classifier was
able to separate the PM group from the M0 with 90%
accuracy (Additional file 3 figure S2, misclassification
error 10%). This PM-PAM classifier included 140 BAC
clones and was, unlike the LM-PAM classifier, employ-
ing probes spread over the whole genome (Additional
file 4 table S2).
Discussion
One of the challenges in CRC therapy lies in the early
detection and treatment of CRC metastases. Elucidation
of the molecular and cellular mechanisms of developing
metastases will play an important role in future diagnos-
tic and therapeutic interventions. A well established
screening method to detect the genetic changes that
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Figure 3 G a i n sa n dl o s s e so ft h eL i v e rM e t a s t a s e s( L M )s a m p l e sv e r s us the Peritoneal Metastases (PM) and No metastases (M0)
samples. Panel showing a zoom of chromosome 20.
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Page 7 of 12underlie carcinogenesis is comparative genomic hybridi-
zation and was first introduced by Kallionemi and col-
leagues in 1992 [32].
In the present study we examine genome wide chromo-
somal aberrations in primary CRC to identify molecular
markers predictive for liver metastases. The method we
chose to examined genome wide chromosomal aberra-
tions is a published and publically available method to
look for recurrent copy number alterations and differen-
tial copy number alteration [31]. The KC-SMART
method was applicable to our research questions and
therefore used. An important principle in the analysis of
this 20q amplification is that a threshold value can be
(arbitrarily) set, but the logistic regression shows a con-
tinuous relationship between the aCGH measurement
and the risk of a liver metastasis. Binarizing the predictive
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Figure 4 ROC curve when using 20q as a predictive value for liver metastasis. This figures shows the Reciever-Operating Characteristic
(ROC) curve for using the mean log
2 ratio of the 20q BAC clones (red) or the mean log
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classfier (blue). AUC = Area Under the Curve.
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Page 8 of 12variable would cause information loss in this case. We
believe that there is more information in the continuous
mean log2 value of the 20q probes than just an on/off
call.
To the best of our knowledge, this is the first study
reporting a classifier predictive for liver metastases in
primary CRC based on genomic aberrations. Our data
demonstrate that primary colorectal tumors that devel-
oped liver metastases are characterized by an amplifi-
cation of chromosome 20q. This amplification of
chromosome 20q occurred significantly more often
in the LM group compared to the other groups (PM
and M0).
In this study there were significantly more left sided
and rectum tumors in the LM group as compared to
the PM group. So far, however, there is no evidence
that peritoneal metastasis are related to the location of
the primary colorectal tumor. These primary lesions are
often characterized as mucinous T4 tumors which
spread tumor cells into the peritoneal cavity [33]. It
might be that left sided and rectum tumors could mod-
ify the penetrance of chromosome 20q and as result
more frequently develop liver metastases. This could
contribute to the fact that left sided and rectal tumors
in our study result more frequently into liver metastases
whereas right sided tumors more often into peritoneal
metastases.
We created a classifier to predict liver metastases in
patients with CRC. This LM-PAM classifier was able to
identify patients who would develop liver metastases and
resulted in an AUC of 0.86. Although the classifier was
constructed by employing cross-validation to obtain
unbiased error estimates, this result should be confirmed
in an independent validation set. Logistic regression ana-
lysis on the mean 20q copy number ratio showed for
every 0.1 log2 20q amplification an odds ratio of 16.2
(90% CI, 2.3-141.2) for developing liver metastases.
Amplification of chromosome 20q has been identified
in several tumor types including breast, ovary, bladder,
pancreas and stomach [32,34-38]. In colorectal cancer,
chromosome 20q has been related to tumor progression,
liver metastases and as an indicator of worse patient
survival [10-13,16,29,39-42]. Knösel et al. created a pro-
gression model to identify relevant chromosomal imbal-
ances specific for metastases but this model was not
created to predict site of metastases in primary CRC
[43]. Recently, Nakao et al. showed that specific copy
number aberrations were linked to nodal metastases and
reported a significant difference in 20q amplification in
primary colorectal tumors between patients who had
liver metastases at time of surgery and those who had
no liver metastases. Unfortunately, they did not propose
a prediction model for liver metastases [44,45]. Diep
et al. presented a genetic pathway for CRC progression
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Page 9 of 12based on a meta-analysis of 31 CGH studies. They iden-
tified specific chromosomal alterations linked to differ-
ent stages of tumor progression and liver metastases
and found that the majority of chromosomal alterations
were present in both primary carcinomas and liver
metastases. They showed that the number of alterations
increases in the transition from primary carcinomas to
liver metastases. Furthermore, they showed that the role
of chromosome 20q was evident in patients with Dukes
D classification [9].
Hence, across all studies, chromosome 20q is of
importance in the development of liver metastases.
Therefore, more understanding of the candidate genes
located on chromosome 20q may guide us to under-
stand the biological mechanisms in the development of
liver metastases. So far, several genes located on 20q
have been described to play an important role in tumor
progression and liver metastases. For example genes
such as CAS/CSE1L, NABC1, ZNF217, Aurora2 (BTAK,
STK15), LIVIN, PTK6, HD54, EEF1A2, PSMA7, TPX2,
AURKA and the ubiquitin-conjugating enzyme E2C
(UBE2C) [10-13,45-51].
These candidate genes located on chromosome 20q
should be taken into account when examining new tar-
geted therapeutic regimens for patients with CRC. For
example, chromosome 20q amplification in CRC showed
in an in vitro study response to Kinesin-5 Inhibitor. This
inhibitor plays a role in the mitotic spindle function in
the cell. Resistance to Kinesin was dominated by ampli-
fication of chromosome 20q. It was suggested that
AURKA and the TPX2 gene located on 20q were the
genes resistance for the Kinesin-5 Inhibitor [51]. Ampli-
fication of 20q could therefore be a potential target for
novel antimitotic cancer therapies.
In summary, organ specific CRC metastases localiza-
tion can be predicted by a LM-PAM classifier on the
basis of specific genomic aberrations in the primary col-
orectal tumor. The validation of the LM-PAM classifier
will further potentiate its role as a tool in clinical prac-
tice. As a result, patients at risk for developing liver
metastases should be frequently screened with modern
imaging tools and are most likely to benefit from addi-
tional chemotherapy.
We show the possibility for specific CGH profiles to
predict CRC metastases target organ with 80% precision.
This is the first tool to do this and as such may provide
the information to guide individual treatment protocols.
In daily clinical practice q-PCR or FISH probes could be
used on FFPE tissue for detecting patients at risk based
on a 20q amplification. We are now developing an
MLPA analysis of chromosome 20q to identify specific
regions involved in the development of liver metastasis.
Table 2 BAC locations on the CGH array representative for chromosome 20
BAC-clone Chr Arm BAC-clone Chr Arm BAC-clone Chr Arm
GS-82-O2 20 p RP11-348I14 20 q RP11-347D21 20 q
GS-1061-L1 20 p RP3-324O17 20 q RP1-155G6 20 q
RP5-852M4 20 p RP5-857M17 20 q RP3-470L14 20 q
RP11-314N13 20 p RP1-310O13 20 q RP4-791K14 20 q
RP4-686C3 20 p RP11-410N8 20 q RP5-1185N5 20 q
RP4-741H3 20 p RP5-1085F17 20 q RP4-530I15 20 q
RP4-599I11 20 p RP4-733O23 20 q RP5-994O24 20 q
RP4-764O22 20 p RP5-1137F22 20 q RP4-715N11 20 q
RP5-1140M3 20 p RP11-353C18 20 q RP4-724E16 20 q
RP4-811H13 20 p RP11-234K24 20 q RP5-1075G21 20 q
RP11-204H22 20 p RP3-469A13 20 q RP5-1162C3 20 q
RP4-742J24 20 p RP4-633O20 20 q RP11-6L15 20 q
RP11-104O6 20 p RP11-122O1 20 q RP5-1167H4 20 q
RP11-526K24 20 p RP4-600E6 20 q RP5-1153D9 20 q
RP5-822J19 20 p RP5-892M9 20 q RP11-46O3 20 q
RP3-348M17 20 p RP4-796I11 20 q RP13-379L11 20 q
RP11-504H3 20 p RP1-128O17 20 q RP1-309F20 20 q
RP1-167O22 20 p RP1-232N11 20 q RP5-827E24 20 q
RP4-788L20 20 p RP1-138B7 20 q RP5-1107C24 20 q
RP1-234M6 20 p RP5-1028D15 20 q RP4-563E14 20 q
RP5-1025A1 20 p RP3-337O18 20 q RP13-152O15 20 q
RP5-1005L2 20 q GS-81-F12 20 q
Bold-Italic: 20q probes used in the LM-PAM classifier
BAC-clone = bacterial artificial chromosome -clone
Chr. = chromosome
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The ability to predict liver metastases based on specific
genomic aberrations in the CRC is important for under-
standing the biology of the tumor, to perform tailored
follow-up and eventually develop targeted therapy in
patients with CRC. Further research should be done by
investigation specific target regions of chromosome 20q.
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Additional file 1: Figure S1. Significant gains (FDR < 0,05) and losses
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